# The distinct contribution of sternotomy to the systemic inflammatory response during children's heart surgery

**Authors:** Joel David Bierer, Julia Paffile, Roger Stanzel, Mark Henderson, John Sapp, Pantelis Andreou, Jean Sylvia Marshall, David Horne

PMC · DOI: 10.3389/fimmu.2025.1617524 · Frontiers in Immunology · 2026-01-02

## TL;DR

This study shows that sternotomy during children's heart surgery triggers a unique inflammatory response involving specific cytokines and chemokines, separate from the effects of cardiopulmonary bypass.

## Contribution

The study identifies a distinct inflammatory mediator profile caused specifically by sternotomy, independent of cardiopulmonary bypass effects.

## Key findings

- Sternotomy significantly increases cytokines and chemokines like IL-1β, CXCL2, and IL-6, but not complement or adhesion molecules.
- PCA-HCPC analysis grouped cytokines and chemokines with the sternotomy phase, while complement and adhesion molecules formed separate clusters.
- Mediators like IL-6, CXCL8, IL-1Ra, and IL-10 are sequentially activated by both sternotomy and cardiopulmonary bypass.

## Abstract

Sternotomy provides access to the mediastinum, heart and great vessels for congenital cardiac surgery in children. The contribution of this incision to the systemic inflammatory response during open-heart surgery, particularly in combination with the complement-mediated response to cardiopulmonary bypass (CPB), is unknown. This study aimed to characterize the inflammatory mediator profile of sternotomy and contrast that with CPB-associated inflammation.

This study is a post-hoc analysis of a single-arm prospective clinical study (NCT05154864) of 40 pediatric patients undergoing congenital cardiac surgery with CPB. Arterial blood samples were taken before and after sternotomy, but before CPB initiation (sternotomy phase), and after CPB exposure (CPB phase). Thirty-three inflammatory mediators from the cytokine, chemokine, complement, and adhesion molecule families were measured. The mediator changes were calculated for each phase and described using median fold changes. A principal component analysis with hierarchical clustering (PCA-HCPC) was conducted on mediator changes over the sternotomy phase.

Compared to baseline, all 16 cytokines and chemokines assessed increased through the sternotomy phase, while complement and adhesion molecules were static or decreased. The most active mediators were IL-1β (3.3x median fold increase), CXCL2 (3.3x), IL-6 (2.6x), IL-10 (2.6x), GM-CSF (2.3x), IL-1α (2.2x) and IL-2 (1.7x). The PCA-HCPC showed three statistically significant clusters, cluster 1 grouped cytokines and chemokines with the sternotomy phase, while complement mediators and adhesion molecules were in separate clusters. In contrast to the CPB exposure, sternotomy showed a predominant contribution of TNF, IL-1α, IL-1β, IL-2, TRAIL, CCL3, CCL4, CXCL1, CXCL2 and GM-CSF to the systemic inflammatory response.

Sternotomy and related tissue trauma produce a distinct systemic inflammatory mediator profile, consisting of pro-inflammatory cytokines and chemokines but not complement. The mediators IL-6, CXCL8, IL-1Ra and IL-10 are sequentially induced by both sternotomy and CPB, representing sequential immunologic stimulation during the cardiac operation.

## Linked entities

- **Proteins:** IL1B (interleukin 1 beta), CXCL2 (C-X-C motif chemokine ligand 2), IL6 (interleukin 6), IL10 (interleukin 10), CSF2 (colony stimulating factor 2), IL1A (interleukin 1 alpha), IL2 (interleukin 2), TNF (tumor necrosis factor), TNFSF10 (TNF superfamily member 10), CCL3 (C-C motif chemokine ligand 3), CCL4 (C-C motif chemokine ligand 4), CXCL1 (C-X-C motif chemokine ligand 1), IL1R1 (interleukin 1 receptor type 1), CXCL8 (C-X-C motif chemokine ligand 8)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}
- **Diseases:** trauma (MESH:D014947), inflammation (MESH:D007249)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12808386/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12808386/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12808386/full.md

---
Source: https://tomesphere.com/paper/PMC12808386